#ICYMI Nacuity had a productive trip in Salt Lake City! CEO Halden Conner presented at the Retinal Therapeutics Innovation Summit G. Michael Wall, PhD & Jami Kern, MBA, PhD, joined 10K+ vision leaders at #ARVO2025 Proud to be part of the progress driving retinal innovation!👏

June is #CataractAwarenessMonth and here at Nacuity Pharmaceuticals, we're developing NPI-002, an implant designed to slow cataract progression by targeting #oxidativestress. Our clinical trial is now enrolling. Learn more: nacuity.com #EyeHealth #VisionCare #Cataracts

We’re proud sponsors of Ushersyndroom’s 5th International Symposium on Usher Syndrome in Nijmegen, Netherlands, June 19-21, 2025. Learn more about this event bringing together the global #USH community: ush2025.org/en/ #USH2025 #RareDisease #DeafBlind #STOPUSH

This #DeafBlindAwarenessWeek, we honor the strength of those living with combined vision & hearing loss. At Nacuity, our #UsherSyndrome #ClinicalTrial reflects our commitment to improve the lives of individuals in this community. Learn more: nacuity.com

We’re excited to announce positive results from our Phase 1/2 SLO-RP trial of NPI-001 for the treatment of retinitis pigmentosa associated w/ #UsherSyndrome, supporting proof of concept and marking a pivotal step toward approval. nacuity.com/news/nacuity-p… #VisionLoss

The #UsherSyndrome Symposium & Ush One See Run/Walk brings the #USHCommunity together in Louisiana. The recent data showing NPI-001 slowed RP progression in #USH, reducing EZ loss by >50% over 2 yrs vs placebo will also be shared. Learn more: hdc.lsuhsc.edu/News1/ush-in-l…

📅 Sept 20 is #UsherSyndromeAwarenessDay #UsherSyndrome is the leading cause of combined #deafness + #blindness. At Nacuity, we’re advancing potential treatments. Check out our new data on our antioxidant therapy for #USH-related #VisionLoss nacuity.com/news/nacuity-p… #USHDay

Congrats to G. Michael Wall, PhD, our SVP & CSO, on being selected as a U.S. Pharmacopeia Expert Committee Volunteer for the 2025–2030 cycle! One of just 350 scientists chosen from 5,000+ applicants worldwide to help set global quality standards for medicines, supplements & food.

The #retina is essential for vision. 👁️ This #WorldRetinaDay, we’re raising awareness of a key driver of retina damage and #visionloss: oxidative stress. We're advancing antioxidant therapies to combat oxidative stress and preserve sight. Learn more: nacuity.com/our-science/

#News: U.S. FDA has granted Breakthrough Therapy Designation for NPI-001 (N-acetylcysteine amide) tablets for the treatment of #RetinitisPigmentosa, highlighting its potential to address significant unmet need in #RP patients living with #VisionLoss. nacuity.com/news/nacuity-p…

#BlindnessAwarenessMonth is about honoring the stories, challenges, and resilience of individuals living with #Blindness and #VisualImpairment. Join Foundation Fighting Blindness in celebrating and sharing these unique stories with the #ShareYourVision campaign! ⭐ fightingblindness.org/shareyourvision

Prioritizing #EyeHealth benefits everyone. 💙 At Nacuity, we’re tackling #VisionLoss from #OxidativeStress, but awareness & education are just as vital. This #WorldSightDay, sign IAPB’s pledge to #LoveYourEyes 👉 iapb.world/world_sight_day

The Nacuity team is heading to Orlando for #AAO2025! This is an exciting time for Nacuity and we look forward to connecting with our #ophthalmology colleagues on our shared our goal to advance eye treatment and care at AAO's annual meeting.

Exciting news for the Usher syndrome community! #USH now has a dedicated ICD-10-CM code, a worldwide standard and recognition for describing diagnoses, conditions and reasons for healthcare visits. Read more: usher-syndrome.org/resources/ushe… #UsherSyndrome

Congrats to our strategic partner Arctic Therapeutics on the EMA Orphan Drug Designation for AT-001 (Nacuity’s NPI-001) to treat Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare and devastating familial #dementia. Learn more: arctictherapeutics.com/arctic-therape…

In #USH news: Foundation Fighting Blindness released four-year, de-identified RUSH2A data giving researchers critical insights to advance therapies for Usher syndrome type 2A and non-syndromic RP and accelerate the path toward meaningful treatments for #IRDs ⬇️ fightingblindness.org/news/rush2a-pu…

Every day matters when your vision is fading. Research supported by Foundation Fighting Blindness is racing to preserve vision, even if just for #OneMoreDay. At Nacuity, we’re advancing a targeted antioxidant therapy for RP linked to #UsherSyndrome. fightingblindness.org/one-more-day

On #IDPWD25, we celebrate the disability community’s strength and resilience, and recognize the barriers that limit equitable opportunities. We're committed to advancing research and developing treatments to create a better future for people living with blinding eye diseases.

In 2025, we made major clinical and regulatory progress to address blinding #eyediseases and chronic conditions driven by #oxidativestress, made possible by our team, patients in our trials, and support of Foundation Fighting Blindness and @RDFund. Here’s to an impactful year ahead.

A variety of factors like oxidative stress can lead to #lowvision. As we work to develop targeted therapies for #retinitispigmentosa and #cataracts, it’s important to raise awareness of #lowvision. Check out Nuclear Energy Institute's resources for #lowvisionawarenessmonth: nei.nih.gov/health/LowVisi…